(Arg) 9
Based on 1 publication(s) in Google Scholar
(Arg)9 (Nona-L-arginine) is a cell-penetrating peptide (CPP) made up of 9 arginine residues, which is an inhibitor of serine endoprotease Furin. (Arg)9 has neuroprotective property, exhibits neuroprotective activity with an IC50 of 0.78 μM in the glutamic acid model.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- CAS. Nr.: 143413-47-2
- Formel: C54H110N36O10
- Molecular Weight:1423.69
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) (Arg) 9
More
Biologische Aktivität
IC50: 0.78 μM (neuroprotection)[1]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
>100 μM
Compound: p-03
|
Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 24 hrs by CCK-8 assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 24 hrs by CCK-8 assay
|
[PMID: 35452935] |
| BEAS-2B | IC50 |
>100 μM
Compound: p-03
|
Cytotoxicity against human BEAS-2B cells assessed as reduction in cell viability measured after 24 hrs by CCK-8 assay
Cytotoxicity against human BEAS-2B cells assessed as reduction in cell viability measured after 24 hrs by CCK-8 assay
|
[PMID: 35452935] |
| HepG2 | IC50 |
>100 μM
Compound: p-03
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 24 hrs by CCK-8 assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 24 hrs by CCK-8 assay
|
[PMID: 35452935] |
| L02 | IC50 |
>100 μM
Compound: p-03
|
Cytotoxicity against human L02 cells assessed as reduction in cell viability measured after 24 hrs by CCK-8 assay
Cytotoxicity against human L02 cells assessed as reduction in cell viability measured after 24 hrs by CCK-8 assay
|
[PMID: 35452935] |
(Arg)9 (Nona-L-arginine; 5-10 μM) provides significant neuroprotection in a dose-response manner following glutamic acid exposure (IC50=0.78 μM). Following kainic acid exposure, (Arg)9 is neuroprotective, but less effective than in the glutamic acid model (IC50=0.81 μM). (Arg)9 also shows neuroprotection following in vitro ischemia (IC50=6 μM)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male Sprague–Dawley rats (270 to 320 g) permanent middle cerebral artery stroke model[2]
-
Dosage:1 μM/kg (600 μL)
-
Administration:Intravenous injection; once, over 5 minutes
-
Result:Reduced significantiy 20% in infarct volume.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS. Nr. 143413-47-2
-
Molecular Weight 1423.69
-
Formel C54H110N36O10
-
Synonyms
Nona-L-arginine; Peptide R9
-
Sequence
Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg
-
Sequence Shortening
RRRRRRRRR
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
Lösungsmittel & Löslichkeit
H2O
Peptide Solubility and Storage Guidelines:
1. Calculate the length of the peptide.
2. Calculate the overall charge of the entire peptide according to the following table:
| Contents | Assign value | |
|---|---|---|
| Acidic amino acid | Asp (D), Glu (E), and the C-terminal -COOH. | -1 |
| Basic amino acid | Arg (R), Lys (K), His (H), and the N-terminal -NH2 | +1 |
| Neutral amino acid | Gly (G), Ala (A), Leu (L), Ile (I), Val (V), Cys (C), Met (M), Thr (T), Ser (S), Phe (F), Tyr (Y), Trp (W), Pro (P), Asn (N), Gln (Q) | 0 |
3. Recommended solution:
| Overall charge of peptide | Details |
|---|---|
| Negative (<0) |
1. Try to dissolve the peptide in water first. 2. If water fails, add NH4OH (<50 μL). 3. If the peptide still does not dissolve, add DMSO (50-100 μL) to solubilize the peptide. |
| Positive (>0) |
1. Try to dissolve the peptide in water first. 2. If water fails, try dissolving the peptide in a 10%-30% acetic acid solution. 3. If the peptide still does not dissolve, try dissolving the peptide in a small amount of DMSO. |
| Zero (=0) |
1. Try to dissolve the peptide in organic solvent (acetonitrile, methanol, etc.) first. 2. For very hydrophobic peptides, try dissolving the peptide in a small amount of DMSO, and then dilute the solution with water to the desired concentration. |
Reinheit & Dokumentation
Verweise
[1]. Cameron A, et al. Polyarginines are potent furin inhibitors. J Biol Chem. 2000 Nov 24;275(47):36741-9. [Content Brief]
[2]. Meloni BP, et, al. The neuroprotective efficacy of cell-penetrating peptides TAT, penetratin, Arg-9, and Pep-1 in glutamic acid, kainic acid, and in vitro ischemia injury models using primary cortical neuronal cultures. Cell Mol Neurobiol. 2014 Mar;34(2):173-81. [Content Brief]
[3]. Meloni BP, et, al. Poly-arginine and arginine-rich peptides are neuroprotective in stroke models. J Cereb Blood Flow Metab. 2015 Jun;35(6):993-1004. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)